pharmaand (pharma&)

pharmaand GmbH Receives Positive CHMP Opinion for Rubraca (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer

CHMP positive opinion based on the results from Phase 3 ATHENA-MONO trial European Commission (EC) approval decision expected in the coming months This is the first rucaparibregulatory milestone since being acquired by pharmaand GmbH in May 2023 16 October 2023 -- Vienna, Austria -- pharmaand (pharma&) announced today that the European Medicines Agency’s (EMA) Committee...
pharmaand GmbH Taborstraße 1 1020 Wien, Austria

+43/1/3560006